These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17045467)

  • 1. Development of starch-based pellets via extrusion/spheronisation.
    Dukić A; Mens R; Adriaensens P; Foreman P; Gelan J; Remon JP; Vervaet C
    Eur J Pharm Biopharm; 2007 Apr; 66(1):83-94. PubMed ID: 17045467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.
    Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C
    Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immediate release of poorly soluble drugs from starch-based pellets prepared via extrusion/spheronisation.
    Dukić-Ott A; Remon JP; Foreman P; Vervaet C
    Eur J Pharm Biopharm; 2007 Nov; 67(3):715-24. PubMed ID: 17537625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of kappa-carrageenan as alternative pelletisation aid to microcrystalline cellulose in extrusion/spheronisation. II. Influence of drug and filler type.
    Thommes M; Kleinebudde P
    Eur J Pharm Biopharm; 2006 May; 63(1):68-75. PubMed ID: 16325384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of disintegrants on the properties of multiparticulate tablets comprising starch pellets and excipient granules.
    Mehta S; De Beer T; Remon JP; Vervaet C
    Int J Pharm; 2012 Jan; 422(1-2):310-7. PubMed ID: 22101283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of kappa-carrageenan as alternative pelletisation aid to microcrystalline cellulose in extrusion/spheronisation. I. Influence of type and fraction of filler.
    Thommes M; Kleinebudde P
    Eur J Pharm Biopharm; 2006 May; 63(1):59-67. PubMed ID: 16326085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting optimal wet granulation parameters for extrusion-spheronisation of pharmaceutical pellets using a mixer torque rheometer.
    Kuhs M; Moore J; Kollamaram G; Walker G; Croker D
    Int J Pharm; 2017 Jan; 517(1-2):19-24. PubMed ID: 27915006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of pellets via extrusion-spheronisation without the incorporation of microcrystalline cellulose: a critical review.
    Dukić-Ott A; Thommes M; Remon JP; Kleinebudde P; Vervaet C
    Eur J Pharm Biopharm; 2009 Jan; 71(1):38-46. PubMed ID: 18771727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of MCC II fraction and storage conditions on pellet properties.
    Krueger C; Thommes M; Kleinebudde P
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1039-45. PubMed ID: 23872176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained release pellets based on poly(N-isopropyl acrylamide): matrix and in situ photopolymerization-coated systems.
    Mayo-Pedrosa M; Alvarez-Lorenzo C; Lacík I; Martinez-Pacheco R; Concheiro A
    J Pharm Sci; 2007 Jan; 96(1):93-105. PubMed ID: 16967440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of extrusion aids for successful production of Kollidon
    Loka NC; Saripella KK; Pinto CA; Neau SH
    Drug Dev Ind Pharm; 2018 Apr; 44(4):632-642. PubMed ID: 29183166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immediate release pellets with lipid binders obtained by solvent-free cold extrusion.
    Krause J; Thommes M; Breitkreutz J
    Eur J Pharm Biopharm; 2009 Jan; 71(1):138-44. PubMed ID: 18805483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-aqueous formulations for ram and screen extrusion-spheronisation.
    Zhang M; Rough SL; Ward R; Seiler C; Wilson DI
    Int J Pharm; 2019 Apr; 560():394-405. PubMed ID: 30763682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physicochemical properties of granulating liquids and their influence on microcrystalline cellulose pellets obtained by extrusion-spheronisation technology.
    Dreu R; Sirca J; Pintye-Hodi K; Burjan T; Planinsek O; Srcic S
    Int J Pharm; 2005 Mar; 291(1-2):99-111. PubMed ID: 15707736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of formulation and excipient variables on the pellet properties prepared by extrusion spheronization.
    Sinha VR; Agrawal MK; Kumria R
    Curr Drug Deliv; 2005 Jan; 2(1):1-8. PubMed ID: 16305403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of partially hydrolysed polyvinyl alcohol for the production of high drug-loaded sustained release pellets via extrusion-spheronisation and coating: In vitro and in vivo evaluation.
    Verstraete G; De Jaeghere W; Vercruysse J; Grymonpré W; Vanhoorne V; Stauffer F; De Beer T; Bezuijen A; Remon JP; Vervaet C
    Int J Pharm; 2017 Jan; 517(1-2):88-95. PubMed ID: 27919698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of crospovidone as pelletization aid as alternative to microcrystalline cellulose: effects on pellet properties.
    Verheyen P; Steffens KJ; Kleinebudde P
    Drug Dev Ind Pharm; 2009 Nov; 35(11):1325-32. PubMed ID: 19832632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation and evaluation of mefenamic acid sustained release matrix pellets.
    Ibrahim MA
    Acta Pharm; 2013 Mar; 63(1):85-98. PubMed ID: 23482315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of microcrystalline cellulose grade and process variables on pellets prepared by extrusion-spheronization.
    Alvarez L; Concheiro A; Gómez-Amoza JL; Souto C; Martínez-Pacheco R
    Drug Dev Ind Pharm; 2002 Apr; 28(4):451-6. PubMed ID: 12056538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control of drug release by incorporation of sorbitol or mannitol in microcrystalline-cellulose-based pellets prepared by extrusion-spheronization.
    Goyanes A; Souto C; Martínez-Pacheco R
    Pharm Dev Technol; 2010 Dec; 15(6):626-35. PubMed ID: 20148708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.